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Abstract 
Early graft loss due to instant blood-mediated inflammatory reactions (IBMIRs) is a 
major obstacle of clinical islet transplantation; inhibition of blood coagulation and 
complement activation is necessary to inhibit IBMIRs. Here, human soluble form 
complement receptor 1 (sCR1) and heparin were co-immobilized onto the surfaces of 
islet cells. sCR1 molecules carrying thiol groups were immobilized through maleimide-
poly(ethylene glycol)–phospholipids anchored in the lipid bilayers of islet cells. Heparin 
was immobilized on the sCR1 layer via the affinity between sCR1 and heparin, and 
additional layers of sCR1 and heparin were formed layer-by-layer. The sCR1 and heparin 
molecules in these layers maintained anti-complement activation and anti-coagulation 
activities, respectively. This promising method could be employed to reduce the number 
of islet cells required to reverse hyperglycemia and prolong graft survival in both allo- 
and xeno-islet transplantation. 
 
 
Keywords: Islet transplantation, Human soluble form complement receptor 1 (sCR1), 
Heparin, Poly(ethylene glycol)-conjugated phospholipid, Instant blood-mediated 











Early graft loss is the major obstacle during transplantation of clinical islets of 
Langerhans (islets) [1]. When islets are transplanted through the portal vein to liver tissue 
in a clinical setting, exposure of the islets to blood triggers a thrombotic/inflammatory 
reaction [2]. Instant blood-mediated inflammatory reactions (IBMIRs) have been 
identified as the main reason for islet loss in the early post-transplantation stage [3]. Two 
to three donors per recipient are generally necessary to achieve insulin dependence [4]. 
Several experimental approaches have been proposed to prevent IBMIRs, including 
systemic treatment [5-8], and although systemic administration of drugs or proteins is 
effective, it is usually associated with a risk of complications and side effects. Therefore, 
local inhibition of the coagulation cascade has also been attempted [9-11]. 
We have also made various attempts [12-16] to suppress IBMIRs using 
amphiphilic polymers such as poly(ethylene glycol)–phospholipid conjugates (PEG-
lipids) and poly(vinyl alcohol) carrying long alkyl side chains. These molecules 
spontaneously incorporate into the cell membrane via hydrophobic interactions between 
the alkyl chains and the lipid bilayer of the cell membrane. In addition, various bioactive 
substances such as urokinase, thrombomodulin, and human soluble form complement 
receptor 1 (sCR1) have been immobilized on islets through the bilayer [17-20]; sCR1 is a 
potent inhibitor of both the classical and alternative complement activation pathways [21-
23], and urokinase and thrombomodulin can inhibit formation of blood clots on the islets.  
In this study, we attempted to engineer both anti-thrombogenic and anti-complement 
properties in the islet cells by co-immobilizing sCR1 and heparin layer-by-layer, and the 
effects of these layers were examined in vitro.  
2. Materials and Methods 
2.1 Purification and thiolation of sCR1 
Human sCR1 was prepared using Chinese hamster ovary (CHO) cells expressing 
sCR1 (CRL-10052
TM
, ATCC; Manassas, VA, USA) as described previously [24]. Briefly, 
CHO cells were maintained in α-MEM medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (FBS; Equitech-Bio, Kerrville, TX, USA), 
100 U/mL penicillin, 100 μg/mL streptomycin (Invitrogen), and 500 nM methotrexate 
(Sigma-Aldrich, St. Louis, MO, USA) to form a confluent cell monolayer. Medium was 
then changed to ASF104 (Ajinomoto Co. Inc., Tokyo, Japan) supplemented with 500 nM 
methotrexate and cultured for an additional 2 days. sCR1 was purified from the 
supernatants by affinity chromatography using a HiTrap Heparin HP column (GE 
Healthcare, Buckinghamshire, UK), and the eluent was further purified with a centrifugal 
filter device (Amicon Ultra -15, 100 kDa; Milipore Corporation, MA, USA). The sCR1 
concentration was determined using a micro BCA protein assay kit (Thermo Fisher 
Scientific, Rockford, IL, USA). 
For thiolation, 1 mL of 3 mg/mL sCR1 solution was mixed with 100 μL of 10 
mg/mL Traut’s reagent in phosphate-buffered saline (PBS; MP Biomedicals, Illkirch, 
France). The solution was left at room temperature for 1 hour, after which thiolated sCR1 
(sCR1-SH) was purified by a Sephadex G25 column (GE Healthcare). Ellman’s reagent 
(Nacalai Tesque, Kyoto, Japan) was used to determine the number of thiol groups per 
sCR1 molecule.  
 
2.2 Surface plasmon resonance (SPR) monitoring of sCR1-heparin interactions  
The interaction between sCR1 and heparin was monitored by an in house-
designed SPR instrument [25], with the SPR sensor surface consisting of a 1-nm 
chromium layer and a 49-nm gold layer on a BK-7 glass plate (refractive index 1.515; 
Arteglass Associates Co., Kyoto, Japan). A self-assembled monolayer (SAM) of 1-
dodecanethiol (Wako Pure Chemical, Osaka, Japan). A hydrophobic monolayer (CH3-
SAM) was formed on the gold-coated glass by incubation in 10 mM 1-dodecanethiol in 
ethanol at room temperature overnight. The glass plate was set on a prism of the SPR 
apparatus and the flow cell was assembled on the glass plate. The intensity of the 
reflected light was monitored in real-time when each solution was applied to the flow cell. 
Maleimide-poly(ethylene glycol)-conjugated phospholipid (Mal-PEG-DPPE) was 
synthesized as described previously [20]. After Mal-PEG-DPPE solution (100 µg/mL in 
PBS) was applied to the CH3-SAM surface, sCR1-SH (100 μg/mL in PBS) was applied 
for 30 min at 37 C. After washing with PBS, heparin (1 mg/mL in PBS) and sCR1 
solutions (100 μg/mL in PBS) were alternately flowed for 30 min at 37 C for each step.  
 
2.3 Immobilization of sCR1 and heparin on the islet surface 
Pancreases from ACI/N rats (8-week-old males; Shimizu Co., Japan) were 
digested by the collagenase method and islets were purified from the digested tissue 
using a discontinuous density gradient of Ficoll/Conray solutions [26]. Islets were 
maintained in culture medium (RPMI-1640; Invitrogen) supplemented with 10% FBS, 
100 U/mL penicillin, and 100 μg/mL streptomycin for 5 days. 
sCR1 and heparin were immobilized on the islet surface as illustrated in Scheme 1. 
Islets were incubated in Mal-PEG-DPPE solution (1 mg/mL in PBS) for 20 min at room 
temperature to prepare the Mal-PEG-islets [20]. After washing with PBS, Mal-PEG-islets 
were incubated in a solution of sCR1-SH (1 mg/mL in PBS) for 1 hour at room 
temperature to allow sCR1 immobilization on the islet surface (sCR1-islets). sCR1-islets 
were washed three times with serum-free medium M199 and incubated in a heparin 
solution (5 mg/mL in medium M199) for 30 min at room temperature to prepare the first 
double-layer (sCR1-heparin) on the islet surface. Subsequent sCR1-heparin layers were 
deposited onto the first layer by incubating sCR1-heparin-islets in sCR1 (500 μg/mL in 
M199) and heparin (5 mg/mL in M199) alternately for 30 min at room temperature until 
the desired number of layers was achieved. Finally, the islets were washed with culture 
medium. 
 
2.4 Observation of sCR1 and heparin immobilized on islet surfaces 
Immunostaining of immobilized sCR1 was carried out using anti-sCR1 J3D3 
antibodies (Invitrogen) as primary antibody and fluorescent-Alexa488 labeled anti-mouse 
antibody (Beckman Coulter, USA) as counterstain. Fluorescein isothiocyanate (FITC)-
conjugated sCR1 (FITC-sCR1) was prepared for islet observation. Briefly, 1 mL of sCR1 
solution (3 mg/mL) was mixed with 100 μL FITC (0.12 mg in 50 μL dimethyl sulfoxide; 
Dojindo Laboratories, Kumamoto, Japan) at a molar ratio of 1:20. The mixture was 
agitated at room temperature for 6 hours. FITC-sCR1 was separated from un-reacted 
reagent using a Sephadex G25 column and stored in the dark at 4 C until use. Stained 
islets were observed with confocal laser scanning microscopy (FLUOVIEW FV500, 
Olympus, Tokyo, Japan).  
FITC-heparin was prepared as described previously [13]. One milliliter of heparin 
(40 mg/mL in pure water) was mixed with FITC (2.6 mg in 100 μL dimethyl sulfoxide) 
and the mixture was left at room temperature overnight. The crude product was 
precipitated in an 8:2 mixture of acetone and diethylether, evaporated, and washed three 
times with acetone. The precipitate was then dialyzed against PBS for 2 days using 
dialysis cassettes (3500 Da; Thermo Scientific) to obtain FITC-heparin. 
 
2.5 Anti-thrombin activity of immobilized sCR1-heparin  
To evaluate the anti-thrombin activity of sCR1-heparin-immobilized substrate 
surfaces, a silicon sheet (10 mm thick) with a hole (6 mm diameter, 4 wells) was placed 
on a CH3-SAM glass plate. One hundred microliters of Mal-PEG-DPPE solution (500 
μg/mL in PBS) was applied to each well and left for 30 min at room temperature. The 
wells were washed five times with PBS. One hundred microliters of sCR1-SH (100 
μg/mL in PBS) was applied to each well and left for 1 hour at room temperature. After 
washing with PBS, heparin (1 mg/mL in PBS) and sCR1 solution (100 μg/mL in PBS) 
were sequentially applied and left for 30 min after each step until the desired number of 
sCR1-heparin layers was formed. As a control, a solution of cystein (1 mM in PBS) was 
added to the Mal-PEG-DPPE-immobilized wells and left for 1 hour. 
Anti-thrombin activity was examined via enzyme-linked immunosorbent assay 
(ELISA) using the Sensolyte® 520 thrombin activity assay kit (AnaSpec, CA, USA) with 
a slight modification. Tris-HCl buffer (100 μL) with or without antithrombin III (10 
μg/mL) and 50 μL thrombin solution (1 μg/mL in assay buffer) was sequentially added to 
each well and the plate was incubated for 10 min at 37 C. Fifty microliters of the 
thrombin-substrate solution were then added to each well. The reaction mixtures were 
incubated for 30 min at 37 C  and the fluorescence (excitation 490 nm, emission 520 
nm) was measured by a fluorophotometer (F-2500; Hitachi, Co., Tokyo, Japan). 
 
2.6 Protective effect of sCR1 from complement-mediated cytotoxicity 
The protective effect of immobilized sCR1 from antibody/complement-mediated 
cytotoxicity was examined as described previously [19, 20]. Blood was drawn from a 
New Zealand white rabbit (20-week-old male; Shimizu Co.), applied to glass test tubes, 
and allowed to clot for 30 min at room temperature. The tubes were centrifuged at 2000 
rpm at 4 C  for 30 min. Serum was collected as the supernatant, pooled, filtered through 
a 200-nm membrane filter, and stored at -80 C until use. The complement in the rabbit 
serum was inactivated by heating the serum at 56 C  for 30 min. Twenty islets from each 
group were incubated in 1 mL of 50% rabbit serum at 37 C. Serum was exchanged every 
24 hours. Islet morphology was observed every 24 hours under a phase contrast 
microscope (IX71, Olympus Optical Co. Ltd., Tokyo, Japan). Insulin levels in the 
collected sera were determined by ELISA (Shibayagi, Gunma, Japan).  
 
2.7 Insulin secretion by modified islets  
A static glucose stimulation assay was carried out to determine whether insulin 
secretion function deteriorates following immobilization of sCR1 and heparin [27]. Fifty 
islets were sequentially incubated in Krebs-Ringer buffer containing 0.1 g/dL or 0.3 g/dL 
glucose, with each incubation proceeding for 1 hour at 37 C. Supernatants were 
collected and insulin concentrations were determined by ELISA. 
3. Results 
3.1 SPR monitoring of sCR1-heparin interactions 
Interactions between sCR1 and heparin on a gold-coated substrate were monitored 
by an SPR apparatus (Fig. 1A). When Mal-PEG-DPPE was applied to the CH3-SAM 
surface, an increase in SPR signal was observed (Fig. 1A), reflecting the immobilization 
of Mal-PEG-DPPE through the hydrophobic interaction between the alkyl chains of 
DPPE and CH3-SAM [20]. When sCR1-SH with an average of 10.8 thiol groups per 
molecule was applied, (Fig. 1A, first arrow), the SPR signal increased, demonstrating 
binding of sCR1 to the maleimide group of Mal-PEG-DPPE. The SPR signal underwent 
step-by-step increases following each application of heparin or sCR1 solutions (arrows, 
Fig. 1A).  
The amounts of sCR1 immobilized after the formation of each double-layer of 
sCR1 and heparin were determined by the BCA assay (Fig. 1B). The amounts of sCR1 
increased with an increase in the number of double-layers (Fig. 1B), an observation 
consistent with the SPR shifts in Fig. 1A. This result demonstrates the formation of 
multiple layers of sCR1 and heparin on the CH3-SAM surface.  
 
3.2 Immobilization of sCR1 and heparin on islet surfaces 
Immobilized sCR1 and heparin layers were introduced layer-by-layer to islet cell 
surfaces (Scheme 1). Cells were treated with Mal-PEG-DPPE to introduce maleimide 
groups on the surface [20], and sCR1-SH was immobilized on the Mal-PEG-treated islet 
surface by the reaction between thiol and maleimide. Heparin and sCR1 were alternately 
added to the surface to form multiple layers. Immunostaining of sCR1 revealed the 
presence of sCR1 on the islets, as indicated by fluorescence at the islet peripheries (Fig. 2, 
panel A1). No fluorescence was observed on islets treated with sCR1 without thiolation 
(Fig. 2, panel A2). As shown in Fig. 2 (panels B1 and B2), FITC-heparin fluorescence 
was observed on the surface of sCR1-islets (Fig. 2, panel B1) but no clear fluorescence 
was detected on naïve islet surfaces (Fig. 2, panel B2), indicating that heparin was 
immobilized via the interaction with sCR1 molecules on the islets.  
We used FITC-sCR1 to examine the stability of multiple sCR1-heparin layers on 
the islets (Fig. 3). The fluorescence intensity increased as the number of layers increased, 
indicating that more sCR1 could be immobilized by increasing the number of layers on 
the islets. Immobilized sCR1 gradually disappeared from islet surface in all cases over 
time (Fig. 3). As expected, the retention time of sCR1 increased when the number of 
layers increased; islets with three sCR1-heparin layers maintained intact morphology 
after three days of culture, indicating that the layer-by-layer method did not influence 
islet viability. 
 
3.3 Anti-thrombin activity of immobilized heparin  
The anti-thrombin activity of heparin immobilized on glass plates (heparin 
composed the outermost layer) by the layer-by-layer method was determined (Fig. 4). 
Anti-thrombin activity was detected neither on PEG-treated substrate nor on the sCR1-
PEG surface. For the substrate surfaces treated with one or three sCR1-heparin layers, 
however, the anti-thrombin activity was significantly increased. The immobilized heparin 
was able to interact with anti-thrombin and activate it to inhibit thrombin. No substantial 
differences in heparin activity were observed between surfaces with one or three sCR1-
heparin layers just after preparation (Fig. 4). The activity of heparin in one double-layer 
gradually decreased with time (Fig. 4), reflecting the detachment of heparin from the 
surface. However, no substantial decreases in activity were observed for three-layer 
constructs (Fig. 4), suggesting that the layer-by-layer method improves heparin stability 
and provides an anti-thrombin effect for at least eight days.   
 
3.4 Protective effect of immobilized sCR1 from complement-mediated cytotoxicity 
We exploited the fact that rabbit serum contains preformed antibodies against rat 
antigens to examine complement-mediated cytotoxicity in our system. Islets, sCR1-islets, 
sCR1-heparin-islets, and islets with three sCR1-heparin layers ((sCR1-heparin)
3
-islets) 
were incubated in 50% rabbit serum; the outermost layer of sCR1-heparin-islets and 
(sCR1/heparin)
3
-islets consisted of heparin. The morphologies of these islets were 
observed over time via phase contrast microscopy (Fig. 5A). Naïve islets were rapidly 
destroyed; a number of swelled cells were already detectable after 1 hour of incubation in 
50% rabbit serum, and more than half of the cells had swelled after 24 hours of 
incubation (Fig. 5A). Most islets were completely destroyed within 48 hours (Fig. 5A). 
When we incubated islets in 50% heat-inactivated rabbit serum, inactivating the 
complement system, no islet damage was observed after 24 hours of incubation (Fig. 5A, 
panels a and b). sCR1-islets, sCR1-heparin-islets, and (sCR1-heparin)
3
-islets maintained 
their morphologies for a longer time than naïve islets (Fig. 5A). After 48 hrs, a small 
number of damaged cells were found at the periphery of the islets.  
When naïve islets were incubated in 50% rabbit serum for 24 hours, a large 
amount of insulin (498.8 ng/20 islets) was found in the supernatant (Fig. 5B). During the 
second 24-hour period, however, the amount of leaked insulin decreased, since only a 
small number of viable islets remained (Fig. 5B). When islets were incubated in 50% 
heat-inactivated rabbit serum, we detected 6.45 ng of insulin from 20 islets, an amount 
comparable to the physiological secretion of insulin by islets. During the first 24-hour 
incubation in 50% rabbit serum, the amounts of insulin leaked from sCR1-islets, sCR1-
heparin-islets, and (sCR1-heparin)
3
-islets were 4.3 ng, 7.2 ng, and 56.8 ng per 20 islets, 
respectively, with the sCR1-islet and sCR1-heparin-islet values at the same level as that 
of naïve islets incubated in heat-inactivated serum. Thus, the islets were effectively 
protected from antibody/complement-mediated cytotoxicity by the immobilized sCR1. A 
relatively high insulin leakage was observed in (sCR1-heparin)
3
-islets due to the slight 
damage of these cells. Substantial insulin leakages were observed in sCR1-islets, sCR1-
heparin-islets, and (sCR1-heparin)
3
-islets during a third 24-hour incubation (Fig. 5B). 
However, insulin leakage decreased with increasing durations of sCR1 immobilization on 
the islets; the protective effect of sCR1 was observed more clearly with (sCR1-heparin)
3
-
islets than with sCR1-heparin-islets (Fig. 5B).  
 
3.5 Glucose-stimulated insulin secretion 
Finally, we examined the effects of sCR1 and heparin immobilization on insulin 
release (Fig. 6). As the glucose concentration in Krebs-Ringer buffer increased from 0.1 
g/dL to 0.3 g/dL, the insulin secretion of naïve islets increased 17.7-fold. Similar insulin 
release behaviors were observed one-layer through five-layer sCR1-heparin-islets (Fig. 6). 
No substantial differences were observed between any groups of islets.  
 
4. Discussion 
In the present study, we modified sCR1 to carry thiol groups and immobilized it 
to islets via maleimide-PEG-lipid (Scheme 1). Heparin was co-immobilized on the islets 
with sCR1 by simple addition of a heparin solution to the islet suspension, because sCR1 
has a strong affinity for heparin [24, 28, 29]. After formation of the first double-layer of 
sCR1-heparin, additional double-layers were easily formed layer-by-layer by simply 
repeatedly alternating the solutions. Previously, heparin was immobilized onto islet 
surfaces via avidin, leading to the evasion of IBMIR [10]. Although effective, this 
method is hardly applicable to human patients because avidin is a xenogeneic protein 
isolated from chicken eggs [30] and thus may cause unfavorable immune reactions.  
We aimed to inhibit blood coagulation and complement activation to prevent early 
islet graft loss caused by IBMIR. Heparin and sCR1, a potent inhibitor of the classical 
and alternative complement activation pathways, were alternately immobilized on islets 
(Scheme 1). Although heparin is known to lose anti-thrombin activity when complexed 
with molecules such as protamine [31], our system demonstrated anti-thrombin activity 
(Fig. 4) and protective effects from antibody/complement cytotoxicity (Fig. 5) regardless 
of the number of sCR1-heparin layers formed on the islets.  
There is no consensus on the period required to inhibit blood coagulation and 
complement activation to prevent early islet graft loss. We aimed to increase the retention 
period of heparin and sCR1 on islets with increasing numbers of sCR1-heparin double-
layers. Heparin in three double-layers exhibited stronger anti-thrombin activity than that 
in one double-layer after 8 days of culture (Fig. 4). sCR1 immunostaining, however, did 
not reveal a clear relationship between sCR1 retention period and the number of double-
layers (Fig. 3). sCR1, however, was clearly seen on the islets regardless of the number of 
double-layers, and the protective effect of immobilized sCR1 was detectable after two 
days of culture. 
The first two days following transplantation are the most severe for islets due to 
IBMIR, specifically the activation of the coagulation system and the complement cascade 
[2, 3]. A large quantity of islets was destroyed in this period. Although immobilized sCR1 
and heparin were gradually released from the cell surface over several days, our approach 
will provide beneficial effects for clinical islet transplantation.     
 
5. Conclusions 
sCR1 and heparin can be alternately immobilized on islet surfaces using a mild 
and simple method that does not deteriorate islet cell viability or function. Anti-
complement activation and anti-coagulation activities were also retained in this system, 
which could be employed to reduce the number of islets required to reverse 
hyperglycemia and prolong graft survival in both allo- and xeno-islet transplantation. 
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Scheme and Figure Captions 
 
Scheme 1.  Immobilization of sCR1and heparin on the islet cell surface. 
 
Figure 1. sCR1 and heparin layer formation via affinity-based interactions. (A) 
Monitoring of sCR1 and heparin layer formation by SPR. A Mal-PEG-DPPE solution 
was applied to CH3-SAM on a gold-coated glass plate, sCR1-SH was applied, and 
heparin and sCR1 were sequentially applied to the surface. (B) The amounts of sCR1 in 
the layers was determined by BCA assay. (sCR1 and heparin) is one double-layer (DL).  
 
Figure 2. Immobilization of sCR1 and heparin on islet surfaces. (A) Immunostaining of 
sCR1 on sCR1-islets (A1) and naive islets (A2). (B) sCR1-islets (B1) and PEG-islets 
(B2) were exposed to FITC-heparin. All islets were observed via confocal laser scanning 
microscopy. (C) Phase contrast image of islets immobilized with three sCR1-heparin 
double-layers after 3 days of culture. Scale bar: 200 μm. 
 
Figure 3. Retention of sCR1 on islet surfaces. Multiple sCR1-heparin layers were formed 
by sequential exposure of sCR1-islets to heparin and sCR1 solutions (1L = one layer, 2L 
= two layers, and so on). FITC-sCR1 was used to visualize immobilized sCR1. Islets with 
multiple layers of sCR1 and heparin were observed by confocal laser microscopy after 
the islets were maintained in culture medium for the indicated periods. Scale bar: 200 μm. 
 
Figure 4. Relative thrombin inactivation activities of multiple sCR1-heparin layers on 
glass plates. The activities were determined after the glass plates were maintained in 
culture medium (medium RPMI-1640 containing 10% FBS) for the indicated periods. 
 
Figure 5. Protective effects of sCR1 from antibody/complement cytotoxicity. (A) Phase 
contrast microscopy of sCR1-islets, sCR1-heparin-islets, (sCR1-heparin)
3–islets, and 
naïve islets maintained in 50% rabbit serum for the indicated periods. Images of islet 
morphology were taken before (a) or after (b) incubation in 50% heat-inactivated rabbit 
serum. (B) Amounts of insulin leakage from the islets into 50% rabbit serum every 24 
hours. 
 
Figure 6. Static glucose stimulation of naïve islets, sCR1-islets, and islets immobilized 
with one, three, or five double-layers of sCR1-heparin. Insulin concentrations were 
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